Related posts
Top Covid-19 Vaccine Stocks to Bet on the Immunization Race (Updated)COVID-19 Stocks to Save Your RRSP + Forecasts and Facts (Updated)Battle of the Top Dividend ETFs : CanadaThis summary was created by AI, based on 3 opinions in the last 12 months.
Sanofi-Aventis (SNY) has recently garnered attention from multiple analysts, with a focus on its growth trajectory and prudent financial management. The company has shown consistent sales growth for three consecutive quarters, exceeding 10%, while effectively utilizing its cash reserves to reduce debt and repurchase shares. With a reasonable earnings multiplier and strong return on equity, the stock presents potential upside as analysts project a price target significantly above its current valuation. Recent concerns over earnings volatility and the spin-off of its consumer healthcare operations may have impacted short-term performance, but experts generally anticipate a potential recovery and upward movement in the stock price.
SNY touched the bottom of its range in October 2023 on weak earnings and news that it would spin-off its consumer healthcare operations. The stock looks to be breaking out and while very hard to predict we think it is possible it trades in a higher new range. The drop last year was likely a one-off driven by the spin-off news, and barring a significant news item as such or consistently weak earnings, we would be surprised if it got back to the low-end of its range.
Unlock Premium - Try 5i Free
Sanofi-Aventis is a American stock, trading under the symbol SNY-N on the New York Stock Exchange (SNY). It is usually referred to as NYSE:SNY or SNY-N
In the last year, 1 stock analyst published opinions about SNY-N. 1 analyst recommended to BUY the stock. 0 analysts recommended to SELL the stock. The latest stock analyst recommendation is . Read the latest stock experts' ratings for Sanofi-Aventis.
Sanofi-Aventis was recommended as a Top Pick by on . Read the latest stock experts ratings for Sanofi-Aventis.
Earnings reports or recent company news can cause the stock price to drop. Read stock experts’ recommendations for help on deciding if you should buy, sell or hold the stock.
1 stock analyst on Stockchase covered Sanofi-Aventis In the last year. It is a trending stock that is worth watching.
On 2025-02-18, Sanofi-Aventis (SNY-N) stock closed at a price of $53.95.
We reiterate SNY as a TOP PICK. Recently reported earnings showed sales growth for the third consecutive quarter that exceeded 10%. Cash reserves are prudently being drawn down to retire debt and buy back shares. It trades at 13x earnings, 1.6x book and supports a 25% ROE. We recommend trailing up the stop (from $42) to $47, looking to achieve $64 -- upside potential of 20%. Yield 2.7%
(Analysts’ price target is $64.00)